FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103543835> ?p ?o ?g. }

• W2103543835 endingPage "1314" @default.
• W2103543835 startingPage "1308" @default.
• W2103543835 abstract "The GPOH-HD (Gesellschaft für Pädiatrische Onkologie und Hämatologie-Hodgkin Disease) strategy for children and adolescents with intermediate and advanced stage Hodgkin lymphoma is based on two induction cycles of OEPA (vincristine, etoposide, prednisone, doxorubicin) followed by COPP (cyclophosphamide, vincristine, procarbazine, prednisone) or COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine) consolidation. The feasibility and efficacy of an intensified procarbazine-free consolidation regimen VECOPA (vinblastine, etoposide, cyclophosphamide, vincristine, prednisone, doxorubicin) were investigated. Following two OEPA and one or two VECOPA cycles, involved field radiotherapy was applied. The main endpoint was feasibility. Secondary endpoints were toxicity, proportion of delayed cycles, granulocyte-colony stimulating factor use, and event-free and overall survival. The regimen was well tolerated with mostly hematotoxicity exceeding Common Toxicity Criteria grade 2. In most patients with advanced stage the second VECOPA cycle was delayed despite hematopoietic recovery and absence of serious adverse events. Event-free survival at 36 months was 0.86 (95% confidence interval 0.70–1). The VECOPA regimen is effective and tolerable. However, its time-intensification was not fully exploited within this trial." @default.
• W2103543835 created "2016-06-24" @default.
• W2103543835 creator A5002564888 @default.
• W2103543835 creator A5006497050 @default.
• W2103543835 creator A5013963069 @default.
• W2103543835 creator A5019784391 @default.
• W2103543835 creator A5020481478 @default.
• W2103543835 creator A5021490889 @default.
• W2103543835 creator A5026240360 @default.
• W2103543835 creator A5027623163 @default.
• W2103543835 creator A5042473693 @default.
• W2103543835 creator A5042661460 @default.
• W2103543835 creator A5046328006 @default.
• W2103543835 creator A5051979326 @default.
• W2103543835 creator A5059343286 @default.
• W2103543835 date "2014-10-09" @default.
• W2103543835 modified "2023-09-30" @default.
• W2103543835 title "Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial" @default.
• W2103543835 cites W126593993 @default.
• W2103543835 cites W1833467461 @default.
• W2103543835 cites W1932077118 @default.
• W2103543835 cites W1967194909 @default.
• W2103543835 cites W2012769063 @default.
• W2103543835 cites W2043778770 @default.
• W2103543835 cites W2054310563 @default.
• W2103543835 cites W2055558717 @default.
• W2103543835 cites W2072292957 @default.
• W2103543835 cites W2084800358 @default.
• W2103543835 cites W2085559416 @default.
• W2103543835 cites W2092939478 @default.
• W2103543835 cites W2101873015 @default.
• W2103543835 cites W2104061870 @default.
• W2103543835 cites W2133487516 @default.
• W2103543835 cites W2162835057 @default.
• W2103543835 cites W2169808607 @default.
• W2103543835 cites W2242925189 @default.
• W2103543835 cites W2254855631 @default.
• W2103543835 cites W2321358810 @default.
• W2103543835 cites W2329201413 @default.
• W2103543835 cites W2410324494 @default.
• W2103543835 cites W4293241248 @default.
• W2103543835 doi "https://doi.org/10.3109/10428194.2014.961011" @default.
• W2103543835 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25204374" @default.
• W2103543835 hasPublicationYear "2014" @default.
• W2103543835 type Work @default.
• W2103543835 sameAs 2103543835 @default.
• W2103543835 citedByCount "4" @default.
• W2103543835 countsByYear W21035438352016 @default.
• W2103543835 countsByYear W21035438352018 @default.
• W2103543835 countsByYear W21035438352020 @default.
• W2103543835 countsByYear W21035438352022 @default.
• W2103543835 crossrefType "journal-article" @default.
• W2103543835 hasAuthorship W2103543835A5002564888 @default.
• W2103543835 hasAuthorship W2103543835A5006497050 @default.
• W2103543835 hasAuthorship W2103543835A5013963069 @default.
• W2103543835 hasAuthorship W2103543835A5019784391 @default.
• W2103543835 hasAuthorship W2103543835A5020481478 @default.
• W2103543835 hasAuthorship W2103543835A5021490889 @default.
• W2103543835 hasAuthorship W2103543835A5026240360 @default.
• W2103543835 hasAuthorship W2103543835A5027623163 @default.
• W2103543835 hasAuthorship W2103543835A5042473693 @default.
• W2103543835 hasAuthorship W2103543835A5042661460 @default.
• W2103543835 hasAuthorship W2103543835A5046328006 @default.
• W2103543835 hasAuthorship W2103543835A5051979326 @default.
• W2103543835 hasAuthorship W2103543835A5059343286 @default.
• W2103543835 hasConcept C126322002 @default.
• W2103543835 hasConcept C141071460 @default.
• W2103543835 hasConcept C143998085 @default.
• W2103543835 hasConcept C181199279 @default.
• W2103543835 hasConcept C185592680 @default.
• W2103543835 hasConcept C2776217839 @default.
• W2103543835 hasConcept C2776694085 @default.
• W2103543835 hasConcept C2776755627 @default.
• W2103543835 hasConcept C2777132456 @default.
• W2103543835 hasConcept C2778119113 @default.
• W2103543835 hasConcept C2778720950 @default.
• W2103543835 hasConcept C2779112685 @default.
• W2103543835 hasConcept C2779219270 @default.
• W2103543835 hasConcept C2779429289 @default.
• W2103543835 hasConcept C2779543040 @default.
• W2103543835 hasConcept C2780964509 @default.
• W2103543835 hasConcept C2781413609 @default.
• W2103543835 hasConcept C55493867 @default.
• W2103543835 hasConcept C71924100 @default.
• W2103543835 hasConceptScore W2103543835C126322002 @default.
• W2103543835 hasConceptScore W2103543835C141071460 @default.
• W2103543835 hasConceptScore W2103543835C143998085 @default.
• W2103543835 hasConceptScore W2103543835C181199279 @default.
• W2103543835 hasConceptScore W2103543835C185592680 @default.
• W2103543835 hasConceptScore W2103543835C2776217839 @default.
• W2103543835 hasConceptScore W2103543835C2776694085 @default.
• W2103543835 hasConceptScore W2103543835C2776755627 @default.
• W2103543835 hasConceptScore W2103543835C2777132456 @default.
• W2103543835 hasConceptScore W2103543835C2778119113 @default.
• W2103543835 hasConceptScore W2103543835C2778720950 @default.
• W2103543835 hasConceptScore W2103543835C2779112685 @default.
• W2103543835 hasConceptScore W2103543835C2779219270 @default.
• W2103543835 hasConceptScore W2103543835C2779429289 @default.

• next